Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14874433 | 0.77 | POLB (0.47) | LMNAMEN1KMT2AALDH1A1POLB | |
| SCHEMBL11310166 | 0.74 | LMNA (0.42) | LMNAMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL7975883 | 0.74 | POLB (0.47) | LMNAMEN1KMT2AALDH1A1POLB | |
| SCHEMBL1042297 | 0.72 | EPHX2 (0.49) | HPGDSMN1; SMN2 | |
| SCHEMBL27091860 | 0.72 | MEN1 (0.65) | LMNAMEN1KMT2AALDH1A1POLB | |
| SCHEMBL7446651 | 0.70 | CYP2D6 (0.50) | LMNAMEN1KMT2ATAAR1HRH3 | |
| SCHEMBL31029938 | 0.70 | LMNA (0.48) | LMNAMEN1KMT2ATAAR1ALDH1A1 | |
| SCHEMBL11020973 | 0.70 | LMNA (0.48) | LMNAMEN1KMT2ATAAR1ALDH1A1 | |
| SCHEMBL12204085 | 0.70 | ALDH1A1 (0.76) | LMNAMEN1KMT2AALDH1A1POLB | |
| SCHEMBL585112 | 0.70 | IDO1 (0.50) | MEN1KMT2ATAAR1ALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9896451-B2 | Method for producing endo-9-azabicyclo[3.3.1]nonan-3-ol derivative | NIPPON SODA CO., LTD. (JP) | 2018-02-20 | — | — | US | disclosed |
| US-20160200726-A1 | METHOD FOR PRODUCING ENDO-9-AZABICYCLO[3.3.1]NONAN-3-OL DERIVATIVE | NIPPON SODA CO., LTD. (JP) | 2016-07-14 | — | — | US | disclosed |
| EP-3042902-A1 | METHOD FOR PRODUCING ENDO-9-AZABICYCLO[3.3.1]NONANE-3-OL DERIVATIVE | Nippon Soda Co., Ltd. (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-5756863-A | Process for preparing optically active cyclohexanol derivatives | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1998-05-26 | — | — | US | disclosed |
| EP-0768288-A2 | Process for preparing optically active cyclohexanol derivatives | Takasago International Corporation (JP) | 1997-04-16 | — | — | EP | disclosed |
| US-RE29990-E | Processes for stereospecifically preparing chiral 2-substituted-4-hydroxy-2-cyclopenten-1-one | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1979-05-08 | — | — | US | disclosed |
| US-4057851-A | PROSTAGLANDIN INTERMEDIATES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1977-11-08 | — | — | US | disclosed |
| US-3968141-A | Processes for stereospecifically preparing chiral 2-substituted-4-hydroxy-2-cyclopenten-1-one | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200726-A1 | METHOD FOR PRODUCING ENDO-9-AZABICYCLO[3.3.1]NONAN-3-OL DERIVATIVE | CYP8B1, CYP2C9, HAAO | LMNA 4766/4885MEN1 2476/4885KMT2A 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.